By TAmiRNA GmbH
To get in touch with TAmiRNA partners with SimplicityBio to create new biomarker offers, simply fill out the form below.
Subscribe to Supplier
TAmiRNA partners with SimplicityBio to create new biomarker offers
The partnership agreement signed in February 2017 aims to create compelling biomarker development services for clients from academia and biotech industry.
Accelerate biomarker projects
The first objective of the partners will be to accelerate TAmiRNA´s current microRNA biomarker projects as a platform for the second step, which is to offer one-stop biomarker development services.
The overall ambition is to be able to offer clients a range of advanced biomarker-based solutions for early diagnosis, prognosis, or patient stratification.
“This partnership consolidates TAmiRNA’s development pipeline and strengthens the competitive advantage of SimplicityBio´s and TAmiRNA´s biomarker development services” commented Dr. Matthias Hackl, CEO of TAmiRNA GmbH.
“This is a move of real significance for biotech and pharma companies participating in clinical studies, universities, clinical research groups and other potential partners seeking to discover and improve microRNA biomarker as well as the development and advancement of existing microRNA biomarker models to make them more sensitive, specific and robust,” added SimplicityBio co-founder and CEO, Dr. Matthew Hall.
Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.
TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”, also known as “models”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.
TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and cancer developing ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations and platelet function in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR) and cardiovascular disease (thrombomiR).
TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include (bio) pharmaceutical companies with drug development programs in human and veterinary medicine, Medtech companies and clinical research groups.
TAmiRNA was founded in November 2013 with funding boosted by investigator awards from the American Society for Bone and Mineral Research (ASBMR) and the European Calcified Tissue Society (ECTS).
TAmiRNA’s founders, Matthias Hackl, Otto Kanzler, Regina & Johannes Grillari share a strong interest in musculoskeletal disorders, especially osteoporosis, and cardio-vascular disease along with a guiding vision “to bring more life into the age of human”.
In May 2015, TAmiRNA was runner-up in the Best of Biotech International Awards. Later that year, the company received Phase 1 funding for its SME instrument and was also named HighTec winner in the GEWINN Young Entrepreneur Awards.
More information available at: http://www.tamirna.com
Privately owned and headquartered in Monthey (Switzerland) SimplicityBio SA is on a mission to be one of the world’s leading biomarker discovery and out-licensing companies leveraging its proprietary machine learning platform BOSSTM – Biomarker Optimization Software System. SimplicityBio aims to capture the disease complexity that is undermining the efficacy of diagnostics and drugs, by discovering and associating novel biomarkers in patient data. The models discovered capture biology’s complexity and are out-licensed to revolution accurate diagnostics, decrease drug development costs and increase treatment efficacy.
Partnerships and consulting agreements are also built around SimplicityBio’s expertise, with a track record of converting research into commercial multi-marker products for example from cancer diagnostics to selection and ranking of biomarkers.
SimplicityBio’s vision is to provide partners and customers with robust biomarkers with biological and therapeutic significance. It helps biotech and medtech companies create robust signatures models by using a panel of biomarkers based on genomics, proteomics or metabolomics (‘omics’) data. These models can be used, for instance, to bring molecular diagnostic tests to market, or for patient stratification in order to develop more effective medicaments.
SimplicityBio is a spin-off from the University of Applied Sciences, Western Switzerland and was incubated at the BioArk in Monthey. The company was founded in 2015 by Miguel Barreto, a Ph.D. in Information Systems from Lausanne University who is an expert in machine learning and bioinformatics; Matthew Hall, a Ph.D. in Biology with advanced knowledge in NextGen Sequencing; and Pedro Faustino, EMBA a specialist in technology.
In April 2017, SimplicityBio has been selected as a finalist for Red Herring’s Top 100 Europe award, a prestigious list honoring the year’s most promising European private technology ventures.
More information available at: http://www.simplicitybio.com